About Celfex
Our Company
Celfex AB is a Swedish biopharmaceutical company based in Goteborg. We are dedicated to developing innovative dermatological treatments that address the unmet needs of patients suffering from Atopic Dermatitis (Eczema).
Our focus is on the development of a proprietary topical Fexofenadine formulation, which has shown promising multi-action potential in treating mild to moderate eczema in both children and adults.
Our Mission
Our passion is to bring dermatology solutions to market which help to relieve children and adults suffering from mild to medium Eczema (Atopic Dermatitis). We believe that innovative approaches to well-known molecules can unlock new therapeutic potential.
Intellectual Property
Celfex AB holds sub-licensed IP covering the topical application of Fexofenadine for the treatment of Atopic Dermatitis, originating with Cellix Bio Private Limited. This IP portfolio includes patents and patent applications protecting our novel formulation and its therapeutic applications.
Our Sponsor
Celfex AB is sponsored by OrchestratePharma GmbH, a Swiss-based company whose orchestrated, co-development approach delivers focused special purpose vehicles such as Celfex. OrchestratePharma licenses the Fexofenadine formulation IP into Celfex AB and provides strategic support and resources for its clinical development and commercialization.